All In Biotech

NDA 016851 · Abbvie

Fml

Fluorometholone · Ophthalmic · Corticosteroid

Last checked: Nov 20, 2026Latest source record: Feb 12, 2013 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1972

Jan 12, 1972

Approved uses

1

Original approval plus efficacy supplements

Registered trials

31

5 Phase 3, 1 recruiting

FAERS reports

3,120

1,612 serious, 316 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 1, 2023.

INDICATIONS AND USAGE Fluorometholone ophthalmic suspension 0.1% is indicated for the treatment of corticosteroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 12, 1972 Original approval · Type 3 - New Dosage Form
1 products under this application
  • FML · FLUOROMETHOLONE 0.1% · SUSPENSION/DROPS, OPHTHALMIC · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Fluorometholone" as an intervention, any sponsor and status, largest first.

All 31 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • treatment failure371
  • drug ineffective232
  • eye pain224
  • off label use217
  • fatigue212
  • diarrhoea180
  • headache177
  • dyspnoea173
  • arthralgia167
  • eye irritation158
  • condition aggravated153
  • dizziness146

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200411
20056
200614
200710
200813
200921
201043
201137
201263
201352
201462
201585
2016176
2017141
2018147
2019168
2020453
2021215
2022234
2023247
2024297
2025353
2026272

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Fml (Fluorometholone)

2024 spending

$113K

Beneficiaries

483

673 claims

Per beneficiary

$233

$25.22 per unit

View as table
YearSpending
2020$215,470
2021$208,061
2022$246,667
2023$243,510
2024$112,737

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 114 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.